Benefits
Antioxidant Protection
Quercetin neutralizes free radicals, reducing oxidative stress that can damage cells and contribute to aging and diseases like cancer and heart disease.
Anti-Inflammatory Effects
It inhibits inflammatory pathways (e.g., reducing cytokines), potentially alleviating chronic inflammation linked to conditions like arthritis or cardiovascular issues.
Immune Support
Quercetin may enhance immune function by modulating immune responses and has shown antiviral properties in some studies, potentially reducing the severity of certain viral infections.
Allergy Relief
It acts as a natural antihistamine, stabilizing mast cells to reduce allergic reactions, which may help with symptoms like sneezing or itching in seasonal allergies.
Heart Health
Quercetin may lower blood pressure, improve cholesterol profiles, and protect against atherosclerosis by reducing oxidative damage to blood vessels.
Brain Health
Preliminary research suggests it may support cognitive function and protect against neurodegenerative diseases (e.g., Alzheimer’s) by reducing inflammation and oxidative stress in the brain.
Exercise Performance
Some studies indicate quercetin may improve endurance and reduce exercise-induced inflammation, though results are mixed.
Mechanism of action
Neurogenesis and Neuroprotection
Stimulates nerve growth factor (NGF) synthesis by activating signaling pathways (e.g., ERK and Akt), promoting neuron growth, repair, and synaptic plasticity. Protects neurons from oxidative stress and apoptosis by upregulating antioxidant enzymes.
Anti-Inflammatory Effects
Reduces pro-inflammatory cytokines (e.g., IL-1β, TNF-α) via inhibition of NF-κB signaling, mitigating brain and systemic inflammation. May decrease microglial activation, linked to neurodegenerative diseases.
Mood Regulation
Modulates monoamine neurotransmitters (e.g., serotonin, dopamine) indirectly through reduced inflammation and enhanced neural connectivity, potentially alleviating anxiety and depression.
Immune Support
Beta-glucans activate macrophages and natural killer cells via pattern recognition receptors (e.g., Dectin-1), enhancing innate immunity. Polysaccharides may increase production of immune-regulating cytokines (e.g., IL-10).
Gut Health
Inhibits growth of harmful bacteria (e.g., H. pylori) through antimicrobial compounds. Strengthens gut barrier function by reducing inflammation and oxidative damage to the gastric mucosa.
Clinical trials
Single-center, open-label, randomized controlled trial at King Edward University, Lahore, Pakistan, in early-stage COVID-19 patients receiving quercetin vs standard care. (Di, Front Pharmacol)
Early COVID-19 outpatients.
Modest improvements in some clinical/inflammatory parameters vs control. Critical caveat: open-label (not blinded — major methodologic concern); single-center; small sample; not definitive evidence. COVID-19 quercetin claims should be interpreted cautiously.
2-week, open-label, randomized controlled trial in 42 outpatients with mild COVID-19 comparing standard care vs standard care + quercetin. (Di)
42 mild COVID-19 outpatients.
Modest reductions in symptom severity and inflammatory markers. Critical caveat: open-label, very small (n=42), industry-funded; weak evidence base. Not supportive of definitive COVID-19 quercetin recommendations.
Randomized, double-blind, placebo-controlled trial of Quercetin Phytosome™ (500 mg/day) for 2 months in adults with chronic fatigue symptoms.
Chronic fatigue patients.
Modest improvements in fatigue scales vs placebo. Note: Quercetin Phytosome™ uses lecithin-based delivery for improved bioavailability (regular quercetin has poor oral bioavailability ~5-15%).
Double-blind, randomized controlled trial of quercetin 500 mg/day for 8 weeks in women with active RA. (J Am Coll Nutr)
Women with active RA.
Modest reductions in clinical disease activity, morning stiffness, and inflammatory markers vs placebo. Note: modern RA care uses biologics (anti-TNF, JAK inhibitors); quercetin at most adjunctive.
Evidence review and pooled analysis of 20 clinical trials (1,164 participants) examining quercetin in metabolic syndrome components.
Pooled across 20 clinical trials.
Quercetin modestly improved BP (small reductions), lipid profile parameters, and inflammatory markers. Effect sizes modest.
Double-blind, randomized controlled trial of quercetin (500 mg/day) in women with T2DM. (J Res Med Sci)
Women with T2DM.
Modest improvements in glucose and lipid parameters vs placebo. Standard T2DM management uses metformin, GLP-1 agonists (semaglutide, tirzepatide), SGLT-2 inhibitors — quercetin adjunctive at most.
Phase 1/2 clinical trial testing dasatinib + quercetin (1,000 mg/day) in patients with diabetic kidney disease. Outcomes: senescent cell burden, kidney function. (EBioMedicine)
Diabetic kidney disease patients.
Senolytic combination modestly reduced senescent cell markers and inflammatory markers. Critical context: dasatinib is a tyrosine kinase inhibitor (cancer drug, prescription only) — combined senolytic regimen is experimental. Not a treatment recommendation. Dasatinib + quercetin senolytic combination is being explored for healthy aging but remains research-stage.
Randomized, double-blind, placebo-controlled trial of quercetin (500 or 1,000 mg/day) vs placebo in adults for URI prevention/management. (— or related)
Adult URI participants.
Modest reductions in URI duration in some subgroups. Effect sizes modest; URI evidence base weaker than typical marketing implies.
Randomized, double-blind, placebo-controlled trial in 60 male physical education students examining 500 mg quercetin + vitamin C vs placebo. Outcomes: oxidative stress, athletic performance.
60 physical education students.
Modest improvements in oxidative stress markers and exercise tolerance vs placebo. Multi-ingredient. Effect sizes modest.